Stammdaten
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Unternehmen & Branche
| Name | Orchestra BioMed Holdings, Inc. |
|---|---|
| Ticker | OBIO |
| CIK | 0001814114 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 221,8 Mio. USD |
| Beta | 0,60 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 33,482,000 | -52,701,000 | -1.11 | 114,857,000 | |
| 2025-09-30 | 10-Q | 861,000 | -20,828,000 | -0.40 | 104,807,000 | |
| 2025-06-30 | 10-Q | 836,000 | -19,363,000 | -0.50 | 42,825,000 | |
| 2025-03-31 | 10-Q | 868,000 | -18,755,000 | -0.49 | 59,051,000 | |
| 2024-12-31 | 10-K | 2,638,000 | -61,024,000 | -1.66 | 76,173,000 | |
| 2024-09-30 | 10-Q | 987,000 | -15,426,000 | -0.41 | 75,319,000 | |
| 2024-06-30 | 10-Q | 778,000 | -15,980,000 | -0.45 | 72,383,000 | |
| 2024-03-31 | 10-Q | 620,000 | -13,463,000 | -0.38 | 82,628,000 | |
| 2023-12-31 | 10-K | 2,760,000 | -49,120,000 | -1.48 | 95,212,000 | |
| 2023-09-30 | 10-Q | 419,000 | -13,316,000 | -0.38 | 116,357,000 | |
| 2023-06-30 | 10-Q | 915,000 | -12,046,000 | -0.35 | 125,883,000 | |
| 2023-03-31 | 10-Q | 1,164,000 | -10,940,000 | -0.40 | 136,281,000 | 99,753,000 |
| 2022-12-31 | 10-K | 3,533,000 | -33,608,000 | -2.24 | 95,572,000 | -6,944,676 |
| 2022-09-30 | 10-Q | 1,163,000 | -10,282,000 | -0.51 | 68,649,053 | -6,067,954 |
| 2022-06-30 | 10-Q | 401,000 | -7,847,000 | -0.77 | 161,583,083 | -5,254,539 |
| 2022-03-31 | 10-Q | 866,000 | -5,729,000 | -0.62 | 161,526,884 | 78,000 |
| 2021-12-31 | 10-K | -378,753 | -0.02 | 161,823,574 | -3,941,965 | |
| 2021-09-30 | 10-Q | -90,411 | 0.00 | 161,882,875 | -3,853,954 | |
| 2021-06-30 | 10-Q | -92,329 | 0.00 | 162,031,351 | -3,763,543 | |
| 2021-03-31 | 10-Q | -108,002 | 162,103,252 | -3,671,214 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RTW INVESTMENTS, LP | 10% Owner | Open Market Sale | -32 | 4.13 | -132.16 | 0,0% | |
| 2025-09-19 | Aryeh Jason | Director | Open Market Purchase | 1,000 | 2.45 | 2,450.00 | +0,5% | |
| 2025-08-01 | PERCEPTIVE ADVISORS LLC | 10% Owner | Open Market Purchase | 700,000 | 2.75 | 1,925,000.00 | +370,8% | |
| 2025-04-30 | RTW INVESTMENTS, LP | 10% Owner | Open Market Purchase | 49,900 | 2.99 | 149,201.00 | +28,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.